All In Biotech

Drug Trial Radar · NCT07719348

A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies

A Phase 1/2, Open Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination With Other Antileukemic Agents in Participants With Selected Myeloid Malignancies

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Sep 15, 2026

Primary completion

Nov 1, 2027

Study completion Sep 30, 2030

Sponsor

Lead sponsor
ServierIndustry
Sponsor type
Industry
First posted
Jul 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of S241656 and to determine the recommended dose for expansion (RDE) of S241656 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML), myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), or chronic myelomonocytic leukemia (CMML). Part 1A dose escalation will determine the RDE to be used in a future expansion stage of the trial. An optional Part 1B drug-drug interaction (DDI) substudy will evaluate the effect of posaconazole on the PK of S241656. The study consists of a screening period of up to 21 days, a treatment period consisting of continuous 28-day cycles of treatment, an end-of-treatment visit, a safety follow-up period, and long-term disease and survival follow-up every 3 months. Participants in the optional DDI substudy may continue treatment in the main study following completion of the DDI assessment period. Participants may undergo bone marrow aspirates and/or biopsies, blood tests, electrocardiograms (ECGs), echocardiograms or multigated acquisition (MUGA) scans, physical examinations, ophthalmologic assessments, and disease response questionnaires.

Conditions

  • Acute Myeloid Leukemia
  • Chronic Myelomonocytic Leukemia
  • Myelodysplastic Syndrome Acute Myeloid Leukemia

Interventions

  • S241656Drug

    Tablets taken by mouth.

  • PosaconazoleDrug

    Tablets taken by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. (Part 1A and 1B) Dose limiting toxicity (DLTs) associated with S241656 during the first cycle of treatmentTime frame: Through Cycle 1 (28 days)
  2. (Part 1A and 1B) Number of Adverse Events (AEs)Time frame: Through 30 days after the last dose of treatment, up to approximately 4 years
  3. (Part 1A and 1B) Number of Serious Adverse Events (SAEs)Time frame: Through 30 days after the last dose of treatment, up to approximately 4 years
  4. (Part 1A and 1B) Severity of AEsTime frame: Through 30 days after the last dose of treatment, up to approximately 4 years
  5. (Part 1A and 1B) Severity of SAEsTime frame: Through 30 days after the last dose of treatment, up to approximately 4 years
  6. (Part 1A and 1B) Duration of AEsTime frame: Through 30 days after the last dose of treatment, up to approximately 4 years
  7. (Part 1A and 1B) Duration of SAEsTime frame: Through 30 days after the last dose of treatment, up to approximately 4 years
  8. (Part 1A and 1B) Number of changes in safety laboratory resultsTime frame: Through 30 days after the last dose of treatment, up to approximately 4 years
  9. (Part 1A and 1B) Number of changes in physical examinationTime frame: Through 30 days after the last dose of treatment, up to approximately 4 years
  10. (Part 1A and 1B) Number of dose reductions due to AEsTime frame: Through end of treatment, up to approximately 4 years
  11. (Part 1A and 1B) Number of dose interruptions due to AEsTime frame: Through end of treatment, up to approximately 4 years
  12. (Part 1A and 1B) Number of dose delays due to AEsTime frame: Through end of treatment, up to approximately 4 years
  13. (Part 1A and 1B) Number of study withdrawals due to AEsTime frame: Through end of treatment, up to approximately 4 years
  14. (Part 1B only) Maximum concentration (Cmax) of S241656Time frame: Through Cycle 1 (28 days)
  15. (Part 1B only) Cmax of metabolite S243796Time frame: Through Cycle 1 (28 days)
  16. (Part 1B only) Time corresponding to Cmax (Tmax) of S241656Time frame: Through Cycle 1 (28 days)
  17. (Part 1B only) Tmax of metabolite S243796Time frame: Through Cycle 1 (28 days)
  18. (Part 1B only) Terminal half-life (t1/2) of S241656Time frame: Through Cycle 1 (28 days)
  19. (Part 1B only) t1/2 of metabolite S243796Time frame: Through Cycle 1 (28 days)
  20. (Part 1B only) Area under the curve (AUC) of S241656Time frame: Through Cycle 1 (28 days)
  21. (Part 1B only) AUC of metabolite S243796Time frame: Through Cycle 1 (28 days)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.